Skip to main content
63°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Adc Therapeutics Sa
(NY:
ADCT
)
3.780
-0.330 (-8.03%)
Streaming Delayed Price
Updated: 3:01 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adc Therapeutics Sa
< Previous
1
2
3
4
5
6
7
Next >
ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022
January 20, 2022
From
ADC Therapeutics
Via
Business Wire
ADC Therapeutics, Mitsubishi Tanabe Ink Zynlonta Licensing Pact In Japan
January 18, 2022
ADC Therapeutics SA (NYSE: ADCT) has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize...
Via
Benzinga
52 Biggest Movers From Friday
January 18, 2022
Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently announced it has received authorization to sell its...
Via
Benzinga
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan
January 18, 2022
From
ADC Therapeutics SA
Via
Business Wire
30 Stocks Moving In Friday's Mid-Day Session
January 14, 2022
Gainers ATI Physical Therapy, Inc. (NYSE: ATIP) shares gained 25.2% to $3.8050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.50 to $5....
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021
November 09, 2021
Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE:
Via
Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 09, 2021
From
ADC Therapeutics
Via
Business Wire
ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting
November 04, 2021
From
ADC Therapeutics SA
Via
Business Wire
71 Biggest Movers From Yesterday
November 03, 2021
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales...
Via
Benzinga
ADC Therapeutics SA (ADCT) Q3 2021 Earnings Call Transcript
November 03, 2021
ADCT earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
November 02, 2021
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®
October 29, 2021
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021
October 27, 2021
From
ADC Therapeutics SA
Via
Business Wire
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma
September 29, 2021
From
ADC Therapeutics
Via
Business Wire
ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors
September 27, 2021
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 23, 2021
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®
September 13, 2021
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics to Participate in Morgan Stanley’s 19th Annual Global Healthcare Conference
September 09, 2021
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces Medical Leadership Transition
September 03, 2021
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty
August 26, 2021
ADC Therapeutics SA (NYSE: ADCT) has entered into a royalty purchase agreement with HealthCare Royalty Partners for up to $325 million. ADC Therapeutics...
Via
Benzinga
ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million
August 26, 2021
From
ADC Therapeutics SA
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021
August 09, 2021
Upgrades DA Davidson upgraded the previous rating for AAON Inc (NASDAQ:
Via
Benzinga
ADC Therapeutics SA (ADCT) Q2 2021 Earnings Call Transcript
August 03, 2021
ADCT earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
August 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
August 03, 2021
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics to Host Second Quarter 2021 Financial Results Conference Call on August 3, 2021
July 28, 2021
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces Encouraging Interim Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) Presented at the 16th Annual International Conference on Malignant Lymphoma
June 22, 2021
From
ADC Therapeutics SA
Via
Business Wire
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
Exposures
Product Safety
ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma
June 18, 2021
From
ADC Therapeutics SA
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.